Catamaran Bio
Meghan Walsh is an accomplished scientist with extensive experience in the biotechnology and pharmaceutical industries, currently serving as Principal Scientist at Catamaran Bio since September 2020. Previous roles include Senior Scientist at Catamaran Bio, Scientist positions at Obsidian Therapeutics and Kyn Therapeutics, Principal Associate Scientist at Compass Therapeutics LLC, and Scientist at Novartis Institutes for BioMedical Research. Meghan began their career at Merrimack Pharmaceuticals, progressing from Senior Research Associate to Associate Scientist, and also held an Associate Scientist role at Biogen. Meghan holds a Master of Science in Biology from Tufts University and a Bachelor of Arts in Biology from Skidmore College.
Catamaran Bio
Catamaran Bio is a newly-formed biotechnology company funded by SV Health Investors. Catamaran is developing transformative off-the-shelf CAR-NK cell therapies.